More recently, sotagliflozin, a dual inhibitor of both SGLT1 and SGLT2, has been approved in the USA to reduce episodes of worsening HF and the risk of cardiovascular death in patients with type 2 diabetes and CKD and in diabetic and non-diabetic patients with HF (regardless of the EF) in the presence of additional risk factors [20]. Here, SLC5A2 is linked to type 2 diabetes mellitus.